Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Investor Presentation (June 2015)
30 slides from Sorrento Therapeutics's investor presentation, June 2015

Slide 1: Next-Generation Cancer Therapeutics
Next-Generation Cancer Therapeutics June 2015 1

Slide 2: Forward Looking Statements
Forward Looking Statements NASDAQ: SRNE Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking

Slide 3: A Comprehensive Approach to Cancer Treatment
A Comprehensive Approach to Cancer Treatment Deep and complementary pipeline creates significant opportunities for novel, breakthrough mono-or combination therapies against cancer. 3

Slide 4: Recent Corporate Events
Recent Corporate Events T26 THERAPCUTCS Off-the-shelf CAR-TNK (Chimeric Antigen Receptor Tumor-attacking Neukoplast®) Sorrento wholly-owned subsidiary Leader in cellular immunotherapy conkwest Exclusive global collaboration to develop next generation ‘off-the-shelf’ CAR.TNK immunotherapies for cance

Slide 5: Sorrento Pipeline Overview
Sorrento Pipeline Overview PDL1.TNK, CD123.TNK, ROR1.TNK, PSMA.TNK, CAR.TNK and G-MAB are trademarks owned by Sorrento Therapeutics, Inc. 5

Slide 6: Immunotherapy Program G-MAB
Immunotherapy Program G-MAB + Neukoplast + Proprietary Toxins & Conjugation Chemistries Bispecific Abs 6

Slide 7: Sorrento's G-MAB Antibody Library
Sorrento’s G-MAB Antibody Library 7

Slide 8: Wholly-owned subsidiary of Sorrento Therapeutics
Wholly-owned subsidiary of Sorrento Therapeutics 8 CAR.TNK and TNK Therapeutics are trademarks owned by Sorrento Therapeutics, Inc.

Slide 9: The Next Generation of the Next Generation
“The Next Generation of the Next Generation” Neukoplast G-MAB Library NK92 cell line (“off-the-shelf”) Vast diversity human antibody library Broad anti-cancer activity in solid and liquid High successful screening rate (over 70 targets screened) tumors Proprietary technologies with FTO No clinical D

Slide 10: Background of NK92 (Neukoplast; aNK)
Background of NK92 (Neukoplast™; aNK) Amplified serial killing Pure NK Line Single source Master Cell Bank Large tank reactor Bioengineerable Missing 'off-switch' No T-cell contamination Batch-to-batch consistency Cryopreservation / Pipeline Enhanced targeting Broad anti-cancer activity No Graft vs.

Slide 11: NK92 is Hypo-Immunogenic and Highly Potent
NK92 is Hypo-Immunogenic and Highly Potent High Granzyme MLR Assay Production Mixed Lymphocyte Reaction (MLR) assay: NK92 do not in NK92 stimulate allogeneic T cells Lymphocytes from 2 healthy donors co- cultured with each other → vigorous proliferation Co-cultured with NK92 (7 days) → no proliferat

Slide 12: Unmodified NK92 Clinically Validated: Phase I
Unmodified NK92 Clinically Validated: Phase I Advanced metastatic disease refractory to chemo, biologics, cytokines, radiation, and surgery Nearly half the patients received multiple dosing regimens (up to 6 months) Promising activity against different cancer types, including acute myelogenous leuke

Slide 13: Phase I Studies: Summary of Findings
Phase I Studies: Summary of Findings Excellent Safety Demonstrated No adverse T-cell induced cytotoxic response A significant safety concern for CAR-T cell approaches No pre-conditioning or combination treatment Notable responses: Melanoma: 1/1 Lung Cancer: 3/4 (1 MR, 2 PR) Renal Cell Cancer: 6/11 (

Slide 14: TNK: CAR-Modified NK92
TNK: CAR-Modified NK92 Clonal cell lines expressing one or more CARs to establish a range of distinct products Multiple killing mechanisms - CAR-targeted as well as broad intrinsic anti- cancer activity of NK92 (“off-target / on-tumor”) Engages the adaptive immune system through cytokine secretion a

Slide 15: HER2.TNK
HER2.TNK In-Vivo Preclinical Mouse Data Homing to HER2-expressing tumors Inhibition of HER2+ RCC metastasis “Serial killing” of HER2-positive target cells even after gamma radiation with Schönfeld et al., Mol Ther. 23(2):330-8, 2015 10 Gy Selective cytotoxicity (spares normal cells) 15

Slide 16: Tumor Homing and Potent Anti-Glioma Activity in Mice
Tumor Homing and Potent Anti-Glioma Activity in Mice Tumor Homing of TNKs Intracranial LN-319 glioblastoma xenografts in NSG mice NK92 FACS Analysis NK92 Her2.TNK NK92 Her2.TNK 16

Slide 17: TNK vs. CAR-T Cells: Key Differentiators
TNK vs. CAR-T Cells: Key Differentiators CAR.TNK CAR-T Cells Cell Production Off-the-shelf universal product; Autologous (patient-derived) via leukapheresis; CAR-modified NK92 cells personalized therapy Transduction Master cell bank Viral transfection & variable CAR expression levels (100% of cells

Slide 18: TNKs being generated by Sorrento
TNKs being generated by Sorrento TNK being generated SORRENTO –CONKWEST COLLABORATION FRAMEWORK: Indications by Sorrento AML CD123.TNK CAR targets selected by Joint Steering Committee. Glioma EGFRviii.TNK CAR.TNKs programs split between both companies. Lead company Glioma EphA3.TNK responsible for a

Slide 19: TNK Development: Next Steps
TNK Development: Next Steps H1 2015 Generation of in-house CARs Generation and evaluation of H2 2015 stable TNK pools and cell lines 2016 IND-enabling studies, IND submission, and initiation of Phase I Studies 19

Slide 20: Anti-PD-L1 mAb Exhibits Potent Activity
Anti-PD-L1 mAb Exhibits Potent Activity 20

Slide 21: Anti-PD-L1 mAb Synergistic with HSP90 Inhibitor In Vivo
Anti-PD-L1 mAb Synergistic with HSP90 Inhibitor In Vivo C57 BL/6 mice bearing MC38 colon carcinomas (n = 7/group) were treated with 200 μg IgG1 control or the anti-PD-L1 antibody STI-A1015 (dosed on day 8, 12 ,and 15), either alone or in combination with 125 mg/kg ganetespib (Synta Pharmaceuticals C

Slide 22: In Vivo Proof-of-Concept of Sorrento ADCs
In Vivo Proof-of-Concept of Sorrento ADCs VEGFR2-ADC STI-D0168 c-MET-ADC STI-D0602 A431 squamous-cell carcinoma cells; maytansinoid drug conjugates 22 ^indicates dosing U87 xenograft; dosing twice weekly; maytansinoid drug conjugates

Slide 23: Resiniferatoxin (RTX): A Novel, Non-opiate Analgesic
Resiniferatoxin (RTX): A Novel, Non-opiate Analgesic Intractable RTX Cancer Pain 23

Slide 24: RTX Target Product Profile
RTX Target Product Profile MOA: Ultrapotent, highly specific TRPV1 agonist selectively targeting afferent neurons Efficacy: Meaningful analgesia with concomitant opioid reduction and improvement in function Safety: Alteration of heat sensation in the targeted area with effect on normal perception /

Slide 25: Two Injection Sites = Two Products for Human Use
Two Injection Sites = Two Products for Human Use Epidural injection into or Spinal Cord Cross Section near the dorsal root ganglion (DRG) for unilateral or diffuse pain Intrathecal injection into the cerebrospinal fluid space (CSF) targeting both DRGs and dorsal horn neurons 25

Slide 26: NIH/NINDS Summary Data Overall
NIH/NINDS Summary Data Overall 12 advanced cancer patients with severe refractory pain have received a single IT RTX injection 15thWorld Congress on Pain (IASP), October 6 –11, 2014, Buenos Aires, Argentina, Poster # PF025: Intrathecal Administration of Resiniferatoxin for Treating Intractable Cance

Slide 27: 2 Patients from New Cohort (2015)
2 Patients from New Cohort (2015) Colorectal Cancer: Stage IV Lung and Rectal Cancer 43 year old female with severe 60 year old male with severe bilateral lower abdominal and rectal pain pelvic and sacral pain Post RTX Post RTX • No pain day after RTX, by day 28 • Substantial pain reduction from 7-1

Slide 28: Next Steps for RTX Development
Next Steps for RTX Development 2015 Complete NIH dose ranging IT safety study (cancer pain) Start NIH POC EpiPG study (cancer-induced bone pain [CIBP]) Complete tox package to support corporate IND for IT RTX Begin tox package to support corporate IND for EpiPG RTX (upper thoracic and lumbar approac

Slide 29: A Comprehensive Approach to Cancer Treatment
A Comprehensive Approach to Cancer Treatment Deep and complementary pipeline creates significant opportunities for novel, breakthrough mono-or combination therapies against cancer. 29

Slide 30: Next-Generation Cancer Therapeutics
Next-Generation Cancer Therapeutics CONTACT: George Uy Henry Ji, Ph.D. Executive Vice President and CCO President and CEO [email protected] [email protected] (661) 607-4057 (858) 668-6923 30
Source: company website
More decks from Sorrento Therapeutics, Inc.
Presentation (August 2023)9 slides · Aug 1, 2023
SPAC Merger (March 2022)21 slides · Mar 18, 2022
Technical Presentation (January 2022)13 slides · Jan 21, 2022
SPAC Merger (December 2021)57 slides · Dec 13, 2021
Technical Presentation (November 2021)9 slides · Nov 29, 2021
Investor Presentation (September 2021)37 slides · Sep 13, 2021